Hamms donate $20M for diabetes center
Harold and Sue Ann Hamm have announced a $20 million gift to
launch a $100 million campaign for the Harold Hamm Oklahoma Diabetes
Center at the University of Oklahoma Health Sciences Center.
"This is the largest single gift in the history of the Health
Sciences Center," said University of Oklahoma President David L.
Boren. "Added to their previous support, Harold and Sue Ann Hamm
have provided more than $30 million to help us create an
internationally top-ranked, university-based center for diabetes
research and clinical care."
The five-year, $100 million campaign seeks to raise money to
"The Harold Hamm Oklahoma Diabetes Center is on a mission to find
a cure," Boren said. "While we work toward that goal, we are
educating people about the challenges of living with diabetes,
teaching them how to prevent the development of diabetes and its
complications and providing the best possible diabetes care."
The center also announced the establishment of a 33-member board
OMRF-tested lupus drug gains FDA approval
The U.S. Food and Drug Administration has approved a new lupus
drug that was tested at the Oklahoma Medical Research Foundation.
Benlysta, the first new lupus drug approved in 56 years, went
through clinical trials led by OMRF physician-scientist Joan
Merrill. The OMRF trials took place in the foundation's Clinical
Pharmacology Research Program, which treats and studies thousands of
Oklahomans suffering from lupus and other autoimmune diseases.
"We were one of the many sites around the world that participated
in several of the studies of this treatment over the years," said
Merrill, who is also medical director for the Lupus Foundation of
America. "This approval is great news for patients."
The OMRF's involvement in the testing of Benlysta began in 2005,
when physicians started administering the drug as part of Phase 2 -
or safety - testing to Oklahoma lupus patients interested in
receiving the experimental treatments. Testing at OMRF continued for
the next six years as the drug progressed to large-scale safety and
efficacy trials and a follow-up safety trial.
One stumbling block to the drug was overcome with OMRF's help.
Patients who took part in OMRF's initial Phase 2 study were given
the option of continuing to receive the drug. Information from their
monthly treatments over the ensuing half-decade helped provide long-
term safety information critical for Benlysta's approval, Merrill
"We're a long way from a cure or even a comprehensive treatment,"
Merrill said. "What this does is give doctors one more tool to help
lupus patients live longer and healthier. And we will continue to
research novel treatments for the disease to give physicians and
patients more and better options."
St. Anthony's receives Medicare awards
St. Anthony Hospital has been named a top performer in a Centers
for Medicare & Medicaid Services Premier health care alliance value-
based purchasing project that rewards hospitals for delivering high-
quality care in six clinical areas.
Based on fifth-year results from the Hospital Quality Incentive
Demonstration project, St. Anthony Hospital earned $42,615 for its
performance in acute myocardial infarction, heart failure, pneumonia
and surgical care improvement project.
St. Anthony also received a Top Improver Award for its results
for acute myocardial infarction, coronary artery bypass graft, heart
failure and hip and knee replacement. …